United States

Fuso Pharmaceutical Industries Ltd (4538.T)

4538.T on Tokyo Stock Exchange

9 Dec 2016
Change (% chg)

¥14 (+0.52%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Fuso Pharmaceutical Industries announces recall of products
Friday, 19 Feb 2016 12:00am EST 

Fuso Pharmaceutical Industries Ltd:Says recall of two kinds of transfusion related products.The recall due to content filling error.  Full Article

Fuso Pharmaceutical Industries amends mid-year outlook for FY 2016
Friday, 30 Oct 2015 02:00am EDT 

Fuso Pharmaceutical Industries Ltd:Says the company increased the mid-year outlook for revenue to 23,200 mln yen from 23,000 mln yen, for the fiscal year ending March 31, 2016.Sees a decrease of operating profit forecast to 180 mln yen from 300 mln yen.Sees a decrease of ordinary profit forecast to 180 mln yen from 200 mln yen.Sees a decrease of net profit forecast to 100 mln yen from 140 mln yen.Sees a decrease of earnings per share to 1.11 yen from 1.55 yen.Says profit outlook lowered due to the increased cost.  Full Article

Otsuka Holdings announces terminations of Otsuka’s contract with OncoTherapy Science and Otsuka’s sublicensing contract with Fuso Pharmaceutical Industries for OTS102
Thursday, 8 Jan 2015 01:00am EST 

Otsuka Holdings Co Ltd:Otsuka Pharmaceutical Co., Ltd. (Otsuka), a wholly-owned subsidiary of Otsuka Holdings Co. Ltd., announces as follows.That the exclusive licensing contract that has been in effect with OncoTherapy Science, Inc. (OTS) for the development, manufacture, and marketing of a peptide therapeutic vaccine for the treatment of pancreatic cancer, will be allowed to expire.The contract will be allowed to expire, following 180-day prior notification, at the scheduled end date of the contract period.A sublicensing contract which has been in effect with Fuso Pharmaceutical Industries, Ltd. for the manufacture and marketing in Japan of OTS102, a therapeutic vaccine, will also be allowed to expire on the same date.Otsuka will continue its efforts in oncology as a priority area. This will include the development of the peptide therapeutic vaccine OCV-C02, for which a phase 1 clinical study is currently underway in colon cancer based on a contract with OTS.  Full Article

3-D Matrix cancels quasi-exclusive distribution agreement with KAKEN PHARMACEUTICAL and Fuso Pharmaceutical Industries
Monday, 22 Dec 2014 01:00am EST 

3-D Matrix Ltd, KAKEN PHARMACEUTICAL CO LTD and Fuso Pharmaceutical Industries Ltd:Cancels quasi-exclusive distribution agreement on TDM-621, which is developed by 3-D Matrix as hemostatic agent, on Dec. 22.  Full Article